Reccan raises 14 MSEK from mainly current owners

Company news
Written by Anna Brodén

The capital injection will support the development of the biomarker panel into a diagnostic test to enable early diagnosis of pancreatic cancer.

Anna Brodén
Previous

Sweden’s Innovation Agency (Vinnova) has granted Reccan 3 M SEK
Next

Reccan Diagnostics successfully raises SEK 15M in a new share issue